Skip to main content
    R

    Replimune Group Inc (REPL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.75
    +0.36 (+3.16%)

    Market Cap: $1.07B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    42%(14/33)
    Avg Surprise
    -24.61%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.79
    Range$-0.82 - $-0.76
    2 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.54-47.3%
    60d ago$-0.56-41.9%
    30d ago$-0.83+5.4%
    7d ago$-0.83+5.4%
    Current$-0.79
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.76
    Range$-0.83 - $-0.69
    2 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.49-55.1%
    60d ago$-0.44-72.7%
    30d ago$-0.79+3.8%
    7d ago$-0.79+3.8%
    Current$-0.76
    Revenue Consensus
    $7M
    Range$0 - $21M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 27EST
    		-$-0.69---
    Dec 26EST
    		-$-0.76---
    Sep 26EST
    		-$-0.79---
    Jun 26
    Reported Aug 14
    		$-0.72$-0.72+0.00%Beat+24.2%
    Mar 26
    Reported Jun 29
    		$-0.76$-0.73-4.11%Miss+7.3%
    Dec 25
    Reported Feb 3
    		$-0.77$-0.82+6.10%Beat+2.5%
    Sep 25
    Reported Nov 6
    		$-0.90$-0.79-13.92%Miss-32.4%
    Jun 25
    Reported Aug 7
    		$-0.95$-0.83-14.46%Miss-21.8%
    Mar 25
    Reported May 22
    		$-0.82$-0.69-18.84%Miss-228.0%
    Dec 24
    Reported Feb 12
    		$-0.79$-0.72-9.72%Miss-2.6%
    Sep 24
    Reported Nov 12
    		$-0.68$-0.74+8.11%Beat+24.4%
    Jun 24
    Reported Aug 8
    		$-0.78$-0.83+6.02%Beat-4.0%
    Mar 24
    Reported May 16
    		$-0.25N/A+68.75%Beat+66.2%
    Dec 23
    Reported Feb 8
    		$-0.77$-0.93+17.20%Beat-11.6%
    Sep 23
    Reported Nov 7
    		$-0.90$-0.89-1.12%Miss-13.9%
    Jun 23
    Reported Aug 3
    		$-0.75$-0.84+10.71%Beat+3.8%
    Mar 23
    Reported May 18
    		$-0.74$-0.66-12.12%Miss-23.3%
    Dec 22
    Reported Feb 9
    		$-0.69$-0.74+6.76%Beat-21.1%
    Sep 22
    Reported Nov 3
    		$-0.79$-0.76-3.95%Miss-41.1%
    Jun 22
    Reported Aug 4
    		$-0.78$-0.56-39.29%Miss-47.2%
    Mar 22
    Reported May 19
    		$-0.60$-0.60+0.00%Beat-46.3%
    Dec 21
    Reported Feb 3
    		$-0.57$-0.57+0.00%Beat-35.7%
    Sep 21
    Reported Nov 4
    		$-0.56$-0.52-7.69%Miss-21.7%
    Jun 21
    Reported Aug 6
    		$-0.53$-0.42-26.19%Miss-20.5%
    Mar 21
    Reported May 20
    		$-0.41$-0.38-7.89%Miss+0.0%
    Dec 20
    Reported Feb 4
    		$-0.42$-0.41-2.44%Miss+8.7%
    Sep 20
    Reported Nov 5
    		$-0.46$-0.44-4.55%Miss-31.4%
    Jun 20
    Reported Aug 7
    		$-0.44$-0.43-2.33%Miss-46.7%
    Mar 20
    Reported Jun 3
    		$-0.41$-0.45+8.89%Beat-173.3%
    Dec 19
    Reported Feb 13
    		$-0.46$-0.36-27.78%Miss-91.7%
    Sep 19
    Reported Nov 11
    		$-0.35$-0.34-2.94%Miss-34.6%
    Jun 19
    Reported Aug 14
    		$-0.30$-0.31+3.23%Beat+85.1%
    Mar 19
    Reported Jun 28
    		$-0.15N/A+62.50%Beat+64.3%
    Dec 18
    Reported Feb 14
    		$-0.24$-0.25+4.00%Beat-
    Sep 18
    Reported Nov 14
    		$-0.26$-0.19-36.84%Miss-
    Jun 18
    Reported Jul 23
    		$-2.02$-0.23-778.26%Miss-
    Mar 18
    Reported Apr 11
    		$-0.42$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-3.73EV/EBITDAN/A
    Price/FCF-4.06xFCF Yield-24.65%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-134.30%ROIC-111.52%
    Financial Health
    Debt/Equity1.00xInterest Coverage-30.00x
    Current Ratio5.23xQuick Ratio5.23x
    Trading Statistics
    Beta0.94Avg Volume2.01M
    52-Week High$16.3352-Week Low$1.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$12.74
    SMA 20$12.85
    SMA 50$13.81
    SMA 200$9.04
    EMA 10$12.51
    EMA 20$12.85
    EMA 50$12.80
    EMA 200$10.15

    MACD

    Line: -0.35Signal: -0.21Hist: -0.14

    ADX

    ADX: 16.2+DI: 12.7-DI: 28.1

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$13.70

    Bollinger Bands

    Upper Band$13.98
    Lower Band$11.72
    %B Position1762%(Upper)
    Band Width0.01

    RSI (14-Day)

    Neutral
    37.7

    Momentum Oscillators

    Stoch %K7.7
    Stoch %D24.3
    Williams %R-80.0
    ROC (10d)-12.6%
    Momentum-1.70
    CCI (20d)-207.7
    MFI (14d)55.7

    Volatility Measures

    ATR (14d)$0.79(6.8%)
    StdDev (20d)0.57
    Hist Vol50.8%(High)

    Volume Flow

    VWAP$11.61
    OBV324.0M
    AD Line29.5M
    CMF (20d)0.060

    Volume Metrics

    Avg Vol (20d)2.1M
    Vol Ratio0.8x
    VWMA (20d)$12.89

    Pivot Points

    R3$13.05
    R2$12.71
    R1$12.05
    Pivot Point$11.71
    S1$11.05
    S2$10.71
    S3$10.05

    Advanced Oscillators

    TSI-14.30
    Ultimate Osc38.8
    KST-89.81

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$1.47M$0$0$0$4.04M$0$0
    Cost of Revenue$0N/A$0$0$0$848,000$0$0$0$655,000$0$0
    Gross Profit$0N/A$0$0$0$-848,000$0$0$0$3.39M$0$0
    Operating Expenses$68.25M$73.34M$71.87M$84.29M$90.42M$79.70M$65.64M$58.92M$57.37M$56.83M$56.54M$63.83M
    R&D$49.28M$52.32M$53.14M$57.88M$57.84M$55.40M$47.63M$43.45M$42.97M$40.66M$42.85M$49.10M
    SG&A$18.97M$21.01M$18.73M$26.41M$32.58M$24.30M$18.02M$15.47M$14.39M$16.18M$13.69M$14.73M
    Operating Income$-68,247,000$-73,338,000$-71,868,000$-84,291,000$-90,422,000$-79,325,000$-66,019,000$-58,916,000$-57,367,000$-58,754,000$-56,540,000$-63,831,000
    Interest Income$1.96M$2.37M$2.85M$3.70M$4.71M$5.88M$5.14M$5.39M$4.71M$5.43M$5.69M$6.05M
    Interest Expense$3.09M$2.88M$1.98M$2.01M$2.00M$1.99M$1.98M$1.97M$1.96M$1.95M$1.55M$1.50M
    Income Before Tax$-69,766,000$-73,457,000$-71,241,000$-83,100,000$-86,693,000$-74,237,000$-65,765,000$-53,055,000$-53,772,000$-55,140,000$-50,647,000$-60,245,000
    Income Tax Expense$0$0$-311,000$0$0$0$575,000$0$0$-65,000$473,000$-201,000
    Net Income$-69,766,000$-73,217,000$-70,930,000$-83,100,000$-86,693,000$-74,130,000$-66,340,000$-53,055,000$-53,772,000$-55,075,000$-51,120,000$-60,044,000
    EBITDA$-67,207,000$-71,886,000$-70,786,000$-85,439,000$-89,270,000$-78,743,000$-69,320,000$-57,206,000$-57,804,000$-62,649,000$-57,162,000$-66,511,000
    EBIT$-68,639,000$-72,949,000$-72,107,000$-84,790,000$-89,411,000$-77,753,000$-69,300,000$-56,480,000$-56,523,000$-60,543,000$-54,781,000$-64,797,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about REPL

    News

    Brokerages set USD 12.00 target for Replimune stock

    Brokerages have set an average target of USD 12.00 for Replimune stock, which is 1.52 percent above its recent Nasdaq price. The company's next earnings are estimated for November 5, 2026...

    ad-hoc-news.de•10/15/26•Somewhat-Bullish

    Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line

    Replimune received accelerated FDA approval for its first commercial drug, Tudriqev, for advanced cutaneous melanoma. While this marks a significant milestone, the company faces a cash crunch...

    Stocktwits•10/8/26•Neutral

    (REPL) Movement as an Input in Quant Signal Sets

    This article analyzes Replimune Group Inc. (NASDAQ: REPL), highlighting neutral near and mid-term readings that could moderate a long-term positive bias. It details an exceptional 134.0:1 risk-reward setup targeting...

    Stock Traders Daily•10/7/26•Neutral

    Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

    Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) and its officers...

    GlobeNewswire•10/6/26•Bearish

    Cantor Fitzgerald reiterates Overweight on Replimune Group stock

    Cantor Fitzgerald has reiterated its "Overweight" rating on Replimune Group (NASDAQ: REPL) following the launch of its drug Tudriqev for melanoma. Despite a significant stock surge...

    Investing.com•10/5/26•Bullish

    REPL Valuation and Fair Value

    P/E
    -3.7x
    P/FCF
    -4.1x
    P/B
    10.8x
    See GNG's fair value

    REPL Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -111.5%
    ROE
    -134.3%
    FCF yield
    -24.6%

    REPL Competitors

    CompanyTicker
    Procept Biorobotics CorpPRCT
    Immatics NVIMTX
    Teladoc IncTDOC
    Enovis CorpENOV
    STAAR Surgical CompanySTAA
    Janux Therapeutics IncJANX
    Amphastar PAMPH
    CureVac NVCVAC

    Sector: Healthcare

    REPL Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    2
    Buy
    5
    Hold
    0
    Sell
    1
    Strong Sell
    0

    REPL Bull Case vs Bear Case

    Bull case

    • 87.5% of REPL's analyst ratings are Buy or Strong Buy.

    Bear case

    • REPL beat EPS estimates in 25.0% of its last 8 reported quarters.

    REPL Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -5.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.79
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About REPL

    Does REPL pay dividends?

    Replimune Group Inc (REPL) does not currently pay a regular dividend.

    What is REPL's market cap?

    Replimune Group Inc (REPL) has a market capitalization of $1.07B with a current stock price of $11.75.

    Related stocks

    Sector: Healthcare

    All stocks starting with R

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In